FIELD: medicine, pharmaceutics.
SUBSTANCE: presented is a group of inventions involving an anticancer agent for combined application of a compound representing N-(2-fluor-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide or its pharmaceutically acceptable salt of formula (I), and the compound 4-[3-chlor-4-(cyclopropylamino-carbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or its pharmaceutically acceptable salt of formula (II), (versions), an anticancer pharmaceutical composition containing the compound of formula (I) and the compound of formula (II), as well as a method of treating cancer. The compound of formula (I) 
, the compound of formula (II) 
.
EFFECT: excellent anticancer effect on various types of cancer as compared to using the declared compounds separately.
5 cl, 5 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER THERAPEUTIC AGENT | 2012 |
|
RU2580609C2 |
| AGENT INTENSIFYING ACTION OF ANTI-CANCER AGENTS | 2012 |
|
RU2589713C2 |
| QUINOLYL-CONTAINING COMPOUND OF HYDROXAMIC ACID, METHOD FOR THEREOF OBTAINING AND APPLICATION IN TREATMENT OF DISEASES, CAUSED BY ABNORMAL PROTEINKINASE AND/OR HYSTONE DEACETYLASE ACTIVITY | 2011 |
|
RU2573633C2 |
| QUINOLINE-LIKE COMPOUND SUBSTITUTED BY PHOSPHORUS-CONTAINING GROUP, METHOD FOR PREPARING IT, THERAPEUTIC COMPOSITION CONTAINING THIS COMPOUND AND USING IT | 2011 |
|
RU2551274C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING QUINOLINE DERIVATIVE | 2010 |
|
RU2548673C2 |
| ANTITUMOUR AGENT INTENSIFIER | 2010 |
|
RU2548913C2 |
| NITROGEN-CONTAINING AROMATIC DERIVATIVES, THEIR USING, MEDICINAL AGENT BASED ON THEREOF AND METHOD FOR TREATMENT | 2001 |
|
RU2264389C2 |
| ANTICANCER DRUG FOR THYROID CANCER | 2007 |
|
RU2448708C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING A TUMOUR | 2018 |
|
RU2750539C2 |
| NEW PHOSPHATE ETHER COMPOUND HAVING A PYRROLOPYRIMIDINE SKELETON, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2020 |
|
RU2801306C2 |
